Non-alcoholic Fatty Liver Disease: East Versus West

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 2, 2012, Pages 122-134

  Agrawal, Swastik ^a   Duseja, Ajay K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cirrhosis; Diabetes mellitus; Gene mutations; Insulin resistance; Metabolic syndrome; Non alcoholic steatohepatitis

Indexed keywords

ADIPONUTRIN; ALPHA TOCOPHEROL; AMINOTRANSFERASE; ANTIOXIDANT; APOLIPOPROTEIN C3; INSULIN SENSITIZING AGENT; MEMBRANE PROTEIN; METFORMIN; PENTOXIFYLLINE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

AFRICAN AMERICAN; AGE DISTRIBUTION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASIA; ASIAN; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CAUCASIAN; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DYSLIPIDEMIA; EASTERN HEMISPHERE; EXERCISE; GENE; GENE MUTATION; HEMOCHROMATOSIS; HEMOCHROMATOSIS GENE; HIGH RISK POPULATION; HISPANIC; HUMAN; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; POPULATION DISTRIBUTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; WEIGHT REDUCTION; WESTERN HEMISPHERE;

EID: 84864110444     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(12)60101-7     Document Type: Article

References (133)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
2. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL, Asia-Pacific Working Party on NAFLD How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?. J Gastroenterol Hepatol 2007, 22:788-793.
3. Chitturi S, Wong VW, Farrell G Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol 2011, 26(Suppl 1):163-172.
4. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010, 51:1593-1602.
5. Amarapurkar D, Kamani P, Patel N, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007, 6:161-163.
6. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009, 84:84-91.
7. Singh SP, Nayak S, Swain M, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol 2004, 25:76-79.
8. Sanyal AJ American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725.
9. Weston SR, Leyden W, Murphy R, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005, 41:372-379.
10. Petersen KF, Dufour S, Feng J, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci USA 2006, 103:18273-18277.
11. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30:1212-1218.
12. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
13. Bernal-Reyes R, Sáenz-Labra A, Bernardo-Escudero R Prevalence of non-alcoholic steatohepatitis. Comparative study with diabetic patients. Rev Gastroenterol Mex 2000, 65:58-62.
14. Duseja A, Bhansali A, Bhadada S, Jain P, Dhiman RK, Chawla Y Nonalcoholic fatty liver disease in patients with recent onset type 2 diabetes mellitus [Abstract]. J Gastroenterol Hepatol 2004, 19(Suppl):A402.
15. Gupte P, Amarapurkar D, Agal S, et al. Nonalcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004, 19:854-858.
16. Merat S, Yarahmadi S, Tahaghoghi S, et al. Prevalence of fatty liver disease among type 2 diabetes mellitus patients and its relation to insulin resistance. Mid East J Dig Dis 2009, 1:74-79.
17. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006, 21:138-143.
18. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005, 15:310-315.
19. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003, 38:954-961.
20. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol 2007, 22:663-668.
21. Hasan I, Gani RA, Machmud R, et al. Prevalence and risk factors for nonalcoholic fatty liver in Indonesia [Abstract]. J Gastroenterol Hepatol 2002, 17(Suppl):S154.
22. Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. Obes Surg 2007, 17:1457-1463.
23. Clark JM, Brancati FL, Diehl AM The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003, 98:960-967.
24. de Lédinghen V, Ratziu V, Causse X, et al. Association Française pour l'Etude du Foie Groupe Epidémiologie et Evaluation; Association Nationale des Gastroentérologues des Hôpitauxgénéraux de France. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol 2006, 45:592-599.
25. Madan K, Batra Y, Panda SK, et al. Role of polymerase chain reaction and liver biopsy in the evaluation of patients with asymptomatic transaminitis: implications in diagnostic approach. J Gastroenterol Hepatol 2004, 19:1291-1299.
26. Dhiman RK, Duseja A Nonalcoholic fatty liver disease. In: Gupta SB. J Assoc Physicians India. Medicine Update 2005, 15:469-475.
27. Jamali R, Khonsari M, Merat S, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol 2008, 14:2867-2871.
28. Chen CH, Huang MH, Yang JC, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007, 22:1482-1489.
29. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292.
30. Amarapurkar DN, Patel ND Clinical spectrum and natural history of non-alcoholic steatohepatitis with normal alanine aminotransferases values. Trop Gastroenterol 2004, 25:130-134.
31. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-666.
32. Poonawala A, Nair SP, Thuluvath PJ Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a casecontrol study. Hepatology 2000, 32:689-692.
33. Ayata G, Gordon FD, Lewis WD, et al. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002, 33:1098-1104.
34. Amarapurkar D, Das HS Chronic liver disease in diabetes mellitus. Trop Gastroenterol 2002, 23:3-5.
35. Nayak NC, Vasdev N, Saigal S, Soin AS End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol 2010, 41:425-430.
36. Duseja A, Sharma BK, Kumar A, et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepatology 2010, 52:2248-2249.
37. Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M, Japan Etiology of Liver Cirrhosis Study Group Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2010, 45:86-94.
38. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
39. Das D, Chattopadhyay D, Aslam T, et al. NAFLD and the changing face of hepatocellular cancer (HCC) [Abstract]. Gut 2011, 60(Suppl 1):A243.
40. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
41. Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008, 43:967-974.
42. Oh KC, Park SH, Park JC, et al. Is the prevalence of cryptogenic hepatocellular carcinoma increasing in Korea?. Korean J Gastroenterol 2005, 45:45-51.
43. Song HY, Lee HK, Lee JS, et al. Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome. Korean J Intern Med 2012, 27:47-52.
44. Takuma Y, Nouso K Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010, 16:1436-1441.
45. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
46. Angulo P, Keach JC, Batts KP, Lindor KD Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
47. Hui AY, Wong VW, Chan HL, et al. Histological progression of nonalcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther 2005, 21:407-413.
48. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 126:113-121.
49. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 2005, 129:113-121.
50. Khurram M, Ashraf MM A clinical and biochemical profile of biopsy-proven non-alcoholic fatty liver disease subjects. J Coll Physicians Surg Pak 2007, 17:531-534.
51. De Lusong MA, Labio E, Daez L, Gloria V Non-alcoholic fatty liver disease in the Philippines: comparable with other nations?. World J Gastroenterol 2008, 14:913-917.
52. Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 2003, 9:1106-1110.
53. Duseja A, Das A, Das R, et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci 2007, 52:2368-2374.
54. Duseja A, Das A, Dhiman RK, et al. Indian patients with nonalcoholic fatty liver disease presenting with raised transaminases are different at presentation. World J Gastroenterol 2007, 13:649-650.
55. Dassanayake AS, Kasturiratne A, Rajindrajith S, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009, 24:1284-1288.
56. Willett WC, Dietz WH, Colditz GA Guidelines for healthy weight. N Engl J Med 1999, 341:427-434.
57. Amarapurkar DN, Amarapurkar AD Nonalcoholic steatohepatitis: clinicopathological profile. J Assoc Phys India 2000, 48:311-313.
58. Agarwal SR, Malhotra V, Sakhuja P, Sarin SK Clinical, biochemical and histological profile of nonalcoholic steatohepatitis. Indian J Gastroenterol 2001, 20:183-186.
59. Duseja A, Murlidharan R, Bhansali A, et al. Assessment of insulin resistance and effect of metformin in nonalcoholic steatohepatitis-a preliminary report. Indian J Gastroenterol 2004, 23:12-15.
60. Steering Committee of the Western Pacific region of the World Health Organization, The International Association for the study of Obesity and the International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia Pty Limited: Melbourne 2000. ISBN 0-9577082-1-1.
61. Deurenberg-Yap M, Chew SK, Deurenberg P Elevated body fat percentage and cardiovascular risks at low body mass index levels among Singaporean Chinese, Malays and Indians. Obes Rev 2002, 3:209-215.
62. Misra A, Misra R Asian Indians and insulin resistance syndrome: global perspective. Metab Syndr Relat Disord 2003, 1:277-283.
63. Ko GT, Chan JC, Cockram CS, Woo J Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. Int J Obes Relat Metab Disord 1999, 23:1136-1142.
64. Misra A, Vikram NK Clinical and pathophysiological consequences of abdominal adiposity and abdominal adipose tissue depots. Nutrition 2003, 19:457-466.
65. Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009, 57:163-170.
66. Tilg H, Diehl AM Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467-1476.
67. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
68. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005, 90:1578-1582.
69. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40:46-54.
70. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
71. Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51:1979-1987.
72. Madan K, Batra Y, Gupta SD, et al. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol 2006, 12:3400-3405.
73. Amarapurkar DN, Patel ND Prevalence of metabolic syndrome in non-diabetic and non-cirrhotic patients with non-alcoholic steatohepatitis. Trop Gastroenterol 2004, 25:125-129.
74. Sreenivasa Baba C, Alexander G, Kalyani B, et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006, 2:191-198.
75. Sung KC, Ryan MC, Wilson AM The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009, 203:581-586.
76. Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007, 30:2940-2944.
77. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 2007, 22:1086-1091.
78. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-238.
79. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
80. Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005, 20:1825-1832.
81. Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004, 106:261-268.
82. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
83. Musso G, Gambino R, De Michieli F, et al. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr 2007, 86:661-671.
84. Madan K, Bhardwaj P, Thareja S, Gupta SD, Saraya A Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol 2006, 40:930-935.
85. Narasimhan S, Gokulakrishnan K, Sampathkumar R, et al. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 2010, 43:815-821.
86. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
87. Pérez-Carreras M, Del Hoyo P, Martín MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003, 38:999-1007.
88. Kowdley KV, Belt P, Wilson LA, NASH Clinical Research Network, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:77-85.
89. Day CP, James OF Steatohepatitis: a tale of two "hits" ?. Gastroenterology 1998, 114:842-845.
90. Graham RM, Chua AC, Carter KW, et al. Hepatic iron loading in mice increases cholesterol bio-synthesis. Hepatology 2010, 52:462-471.
91. Valenti L, Fracanzani AL, Bugianesi E, et al. HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2010, 138:905-912.
92. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999, 31:421-429.
93. Duseja A, Das R, Das A, Dhiman RK, Chawla Y, Garewal G Serum iron levels and hepatic iron overload in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006, 51:1730-1731.
94. Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 2005, 11:393-395.
95. Yamauchi N, Itoh Y, Tanaka Y, et al. Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE mutation in Japanese patients with nonalcoholic steatohepatitis. J Gastroenterol 2004, 39:654-660.
96. Chitturi S, Weltman M, Farrell GC, et al. HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002, 36:142-149.
97. Miller M, Rhyne J, Chen H, et al. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res 2007, 38:444-451.
98. Petersen KF, Dufour S, Hariri A, et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010, 362:1082-1089.
99. Kozlitina J, Boerwinkle E, Cohen JC, Hobbs HH Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011, 53:467-474.
100. Valenti L, Nobili V, Al-Serri A, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 2011, 55:1409-1414.
101. Li Y, Xing C, Cohen JC, Hobbs HH Genetic variant in PNPLA3 is associated with nonalcoholic fatty liver disease in China. Hepatology 2012, 55:327-328.
102. Peter A, Kantartzis K, Machicao F, et al. Visceral obesity modulates the impact of apolipoprotein C3 gene variants on liver fat content. Int J Obes (Lond) 2011, [Epub ahead of print].
103. Duseja A, Aggarwal R APOC3 and PNPLA3 in non-alcoholic fatty liver disease: need to clear the air. J Gastroenterol Hepatol 2012, 27:848-851.
104. Cox AJ, Wing MR, Carr JJ, et al. Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus. Diabetes Metab 2011, 37:452-455.
105. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
106. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1209-1217.
107. Valenti L, Alisi A, Galmozzi E, et al. I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology 2010, 52:1274-1280.
108. Zain SM, Mohamed R, Mahadeva S, et al. A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Hum Genet 2012, [Epub ahead of print].
109. Sookoian S, Pirola CJ Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53:1883-1894.
110. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
111. Park JW, Jeong G, Kim SJ, Kim MK, Park SM Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol 2007, 22:491-497.
112. Wong VW, Wong GL, Tsang SW, et al. Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Aliment Pharmacol Ther 2009, 29:387-396.
113. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010, 59:969-974.
114. Harrison SA, Torgerson S, Hayashi PH The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003, 98:2042-2047.
115. Farrell GC, Larter CZ Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43(2 Suppl 1):S99-S112.
116. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis. J Gastroenterol Hepatol 2009, 24:248-254.
117. Hashimoto E, Yatsuji S, Tobari M, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009, 44(Suppl 19):89-95.
118. Starley BQ, Calcagno CJ, Harrison SA Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
119. Ong JP, Pitts A, Younossi ZM Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008, 49:608-612.
120. Sookoian S, Pirola CJ Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008, 49:600-607.
121. Targher G, Day CP, Bonora E Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
122. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009, 50:68-76.
123. Wang CL, Liang L, Fu JF, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol 2008, 14:1598-1602.
124. Musso G, Gambino R, Cassader M, Pagano G A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010, 52:79-104.
125. Madan K, Batra Y, Gupta DS, et al. Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. Indian J Gastroenterol 2005, 24:251-255.
126. Satapathy SK, Garg S, Chauhan R, et al. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004, 99:1946-1952.
127. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:634-638.
128. Lee YM, Sutedja D, Wai CT, et al. A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008, 2:196-201.
129. Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004, 19:537-544.
130. Omer Z, Cetinkalp S, Akyildiz M, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010, 22:18-23.
131. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008, 14:6395-6400.
132. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6:1396-1402.
133. Kakizaki S, Takizawa D, Yamazaki Y, et al. Nonalcoholic fatty liver disease in Japanese patients with severe obesity who received laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in comparison to non-Japanese patients. J Gastroenterol 2008, 43:86-92.